{
    "clinical_study": {
        "@rank": "72187", 
        "acronym": "CES1", 
        "arm_group": [
            {
                "arm_group_label": "CES1 gene variant group", 
                "arm_group_type": "Experimental", 
                "description": "Oseltamivir 75 mg 1 cap"
            }, 
            {
                "arm_group_label": "CES1 gene wild type group", 
                "arm_group_type": "Experimental", 
                "description": "Oseltamivir 75 mg 1 cap"
            }
        ], 
        "brief_summary": {
            "textblock": "Investigate genetic variability of CES1 gene on pharmacokinetics of oseltamivir in healthy\n      Korean volunteers."
        }, 
        "brief_title": "A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Oseltamivir", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy subjects:\n\n          1. Agreement with written informed consent\n\n          2. Adult healthy male or female subject age 20 to 45\n\n        Exclusion Criteria:\n\n          1. Clinically significant, active gastrointestinal system, cardiovascular system,\n             pulmonary system, renal system, endocrine system, blood system, digestive system,\n             central nervous system, mental disease or malignancy\n\n          2. Medication with any drug which may affect the pharmacokinetics of oseltamivir  within\n             14 days\n\n          3. Previously donate whole blood within 30 days or Previously participated in other\n             trial within 60 days\n\n          4. Subject with known for hypersensitivity reactions to oseltamivir\n\n          5. Subject who perform contraception during study periods\n\n          6. Female woman who are pregnant or are breast feeding\n\n          7. An impossible one who participates in clinical trial by investigator's decision\n             including laboratory test result"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902342", 
            "org_study_id": "CES01"
        }, 
        "intervention": {
            "arm_group_label": [
                "CES1 gene variant group", 
                "CES1 gene wild type group"
            ], 
            "intervention_name": "Oseltamivir 75 mg 1 cap", 
            "intervention_type": "Drug", 
            "other_name": "Tamiflu"
        }, 
        "intervention_browse": {
            "mesh_term": "Oseltamivir"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-768"
                }, 
                "name": "Seoul National University Hospital Clinical Trial Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Pharmacokinetic Characteristics of Oseltamivir in Healthy Korean Volunteers", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Kyoung Soo Lim, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Maximum plasma concentration (Cmax), Area under the plasma concentration curve (AUClast and AUCinf)", 
                "measure": "Oseltamivir pharmacokinetic parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 0 to 48 h post dose"
            }, 
            {
                "description": "Maximum plasma concentration (Cmax), Area under the plasma concentration curve (AUClast and AUCinf)", 
                "measure": "Oseltamivir carboxylate pharmacokinetic parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 0 to 48 h post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902342"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "first time to reach Cmax (tmax), terminal half-life (t1/2z), apparent clearance (CL/F), apparent renal clearance (CLR/F), metabolic ratio", 
                "measure": "Other oseltamivir pharmacokinetic parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 0 to 48 h post dose"
            }, 
            {
                "description": "first time to reach Cmax (tmax), terminal half-life (t1/2z), apparent clearance (CL/F), apparent renal clearance (CLR/F), metabolic ratio", 
                "measure": "Other oseltamivir carboxylate pharmacokinetic parameters", 
                "safety_issue": "No", 
                "time_frame": "Up to 0 to 48 h post dose"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}